BF

Butterfly Network, Inc.

BFLYHealthcareNASDAQ

Medical Devices · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$97.6M
+19.0% YoY
Net Income
-$77.1M
-6.3% YoY
EBITDA
-$67.4M
-10.6% YoY
Free Cash Flow
$925,625

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 1CONFIRMED RSI OversoldRSI 28.5, below 30, stock may be oversold
Aug 27 MACD Negative CrossoverHistogram -0.0791, negative momentum
About Butterfly Network, Inc.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. With a market capitalization of $1.96B, it sits in small-cap territory. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market.

Where BFLY stands vs its 150-day and 200-day moving averages

As of the September 1, 2026 close, BFLY finished 41.65% above its 150-day moving average ($5.57) and 56.55% above its 200-day moving average ($5.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is BFLY overbought or oversold?

At the September 1, 2026 close, BFLY's RSI(14) was 28.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.96B
Fwd P/E-147.20
EPS$-0.29
Beta2.09
52W Change+365.8%
ROE-35.5%
Analysis

The balance sheet looks solid with $124.7M in cash comfortably exceeding the $19.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $926K supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -35.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $62.6M (2021) to $97.6M (2025), reflecting a 56% increase over the period.

A beta of 2.09 means BFLY is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BFLY.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms